Aerie Pharma (AERI)
In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Aerie Pharma, with a price target of $24.00. The company’s shares closed last Monday at $11.92, close to its 52-week low of $10.80.
According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 3.6% and a 37.8% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, GW Pharma, and Otonomy.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $30.75, which is a 134.4% upside from current levels. In a report issued on July 17, Needham also assigned a Buy rating to the stock with a $32.00 price target.
Quest Diagnostics (DGX)
Wells Fargo analyst Dan Leonard maintained a Hold rating on Quest Diagnostics today. The company’s shares closed last Monday at $124.98, close to its 52-week high of $131.81.
According to TipRanks.com, Leonard is a 4-star analyst with an average return of 6.9% and a 62.6% success rate. Leonard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Mettler-Toledo, and IQVIA Holdings.
Quest Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $138.60, which is an 11.0% upside from current levels. In a report issued on July 14, Credit Suisse also assigned a Hold rating to the stock with a $128.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.